Royal Bank of Canada
UTHR icon

Royal Bank of Canada’s United Therapeutics UTHR Stock Holding History

Royal Bank of Canada’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-31,400
Closed -$5.41M – 6730
2015
Q1 		$5.41M Buy
31,400
+13,100
+72% +$2M ﹤0.01% 1551
2014
Q4 		$2.37M Sell
18,300
-91,600
-83% -$11.8M ﹤0.01% 2200
2014
Q3 		$14.1M Buy
+109,900
New +$11.3M 0.01% 1015

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Royal Bank of Canada's UTHR Position: Q1 2026 in Review

Royal Bank of Canada increased its United Therapeutics (UTHR) stake by 3.3% in Q1 2026, buying an estimated $928K and bringing the position to 59,152 shares worth $35.1M. The position accounts for 0.01% of the portfolio, ranked #1111.

Royal Bank of Canada first reported a position in UTHR in Q2 2013 and has held it in 52 quarters since. 852 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Royal Bank of Canada held 59,152 shares of United Therapeutics worth $35.1M as of Q1 2026.
  • Royal Bank of Canada bought 1,864 United Therapeutics shares in Q1 2026, an estimated $928K.
  • United Therapeutics made up 0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #1111 holding.
  • Royal Bank of Canada first reported a position in United Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • 852 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.